E-DRUG: Event on transparency and clinical trials in the Europe 17/10 European Parliament
------------------------------------------------------------------------------------------------
Transparency and clinical trials in the European Union. Obstacles, constraints and opportunities.
Since 2013, the European Parliament and other European Union (EU) institutions have endorsed reforms of clinical trial regulations that would ensure greater transparency and accountability. However, implementation of these essential amendments is being hindered due to a lack of commitment from a number of key actors.
Join Health Action International and TranspariMED for a public discussion hosted by Michèle Rivasi MEP (Greens, DEVE/ENVI) on the EU Clinical Trial Regulation and how it contributes to greater transparency. We will try to find answers to the following questions:
How can we ensure that transparency is enforced?
How can relevant stakeholders best utilise open and transparent clinical trial data for the benefit of patients?
What role should be played by the EU institutions?
How would recent efforts aimed at achieving greater transparency in R&D data link to greater accountability for clinical trials?
SPEAKERS
Fergus Sweeney | Head of Inspections, Human Medicines Pharmacovigilance and Committees Division, European Medicines Agency
Kristof Bonnarens | Policy Officer Pharmaceuticals, European Commission, DG Sante
Sylvia de Haan | Head of External Affairs & Geographic Groups' Support, Cochrane
Rachel Cooper | Director, Transparency International Health Initiative
Till Bruckner | Founder, TranspariMED
Jaume Vidal | Senior Policy Advisor, Health Action International
Moderator: Rita Kessler | European Advocacy Officer, Prescrire
Please register by 11 October at
bit.ly/TransparentTrials
Event Language is English, translation into French is offered.
Light lunch will be provided.
JAUME VIDAL
Senior Policy Advisor, European Projects
Health Action International
Jaume Vidal <jaume@haiweb.org>